Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Agriculture technology specialist CropLogic has continued its love affair with the hemp industry after announcing an AU$15.4 million deal today – to supply Oregon hemp farmers Deschutes Labs with its services and biomass energy
  • This news today is in addition to CropLogic successfully planting 500 acres of cannabidiol, or CBD, producing hemp crops in June
  • Deschutes Labs has not officially kicked off production at its facility, but the company is already poised to produce 10,000 pounds of hemp biomass per day
  • CropLogic is commonly contracted to provide its services of real-time crop management data and aerial imagery to farmers across New Zealand, Australia and America

ASX-listed company CropLogic has used its positioning in Oregon to expand interest in the hemp business, starting today off with an AU$15.4 million deal.

The deal, signed with hemp farmers Deschutes Labs, will see CropLogic provide its crop management software and services to boost the client’s operations.

CropLogic will also be supplying renewable energy known as biomass to the farmers.

As Deschutes is self-claimed to be ‘fairly new’, the company is already poised to pump out over 10,000 pounds of industrial hemp biomass a day.

So how will CropLogic be helping them out?

The company specialises in combining management technology with crop farming. CropLogic clients commonly use technology for aerial imagery and real-time data tracking.

Starting this October CropLogic’s subsidiary, Logical Cropping will be supplying Deschutes a weekly allotment of the biomass energy.

Each delivery will be followed with a payment from Deschutes, eventually totalling AU$15.4 million.

Today’s news also follows CropLogic’s successful planting of 500 acres of CBD producing hemp crops – which commenced on June 25.

“This initial sale confirms that CropLogic’s agronomy, farm management and tech expertise can be successfully applied to industrial hemp and has been recognised by industry participants,” CropLogic CEO James Cooper-Jones said.

“This Supply Agreement establishes CropLogic as a viable producer and assists in developing credibility amongst other hemp farmers that we are pitching to,”

As well, Deschutes Labs Manager Anthony Vivolo says his company is focused on producing the highest quality of hemp extracts and having CropLogic on its side is integral.

“Through our relationship with CropLogic, a growing partner offering a vast knowledge in hemp genetics, we can offer our customers consistent and abundant CBD products,”

CBD, or cannabidiol, is the extract from hemp used in food, medication, soaps, oils and creams. CBD is commonly used for treating epilepsy, Alzheimer’s and some times cancer.

Although the greater market around the globe has not fully embraced using CBD in pharmaceuticals yet, the market has seen an uptake over the last few years due to loosening laws in the West.

“Our mission is to produce the highest quality hemp extracts and isolates from premium American grown industrial hemp,” added Anthony.

“We are proud to be a reputable CBD wholesaler offering quality, consistency, and accountability,”

Operations have not officially kicked off for Deschutes yet, as the company readies to begin production in September.

Deschutes’ managing team already boasts experience in the hemp industry.

Share prices in CropLogic this morning are trading at a 10.3 per cent premium for 8.6 cents a share. The company’s market cap is valued for $29.6 million.

CLI by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.